04:47 PM EDT, 05/16/2024 (MT Newswires) -- Matt Abernethy, Chief Financial Officer, on May 14, 2024, sold 30,000 shares in Neurocrine Biosciences ( NBIX ) for $4,138,436. Following the Form 4 filing with the SEC, Abernethy has control over a total of 31,528 shares of the company, with 31,528 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/914475/000091447524000121/xslF345X03/wk-form4_1715892031.xml